A new study published in The Lancet suggests that Semaglutide — widely known under the brand name Ozempic — may reduce alcohol cravings in people with alcohol use disorder.
The clinical trial involved patients with alcohol dependence who received low doses of semaglutide or a placebo as part of standard monitoring. Over approximately 26 weeks, researchers evaluated changes in alcohol consumption levels and the intensity of cravings.
The results showed that patients receiving semaglutide experienced a greater reduction in alcohol intake and episodes of heavy drinking compared to the control group. Participants also reported decreased subjective cravings for alcohol, suggesting that the drug may affect not only behavioral habits but also reward mechanisms in the brain.
Researchers believe the effect may be linked to the action of GLP-1 class medications, which were originally developed to treat Type 2 Diabetes and obesity. These drugs influence signaling pathways involved in appetite regulation and the brain’s reward system, which could help explain the reduced dependence not only on food but also on alcohol.
At the same time, the authors stress that semaglutide has not yet been approved for the treatment of alcohol use disorder. Additional studies are needed to assess the long-term effectiveness, safety, and potential role of such medications in addiction treatment.
Follow NEWS.am Medicine on Facebook and Twitter
month
week
day